Challenges in sentinel node (SN) pathology in the era of adjuvant treatment: The risk of over and undertreatment stress the need for expert pathology review. Background: Pembro, a PD-1 inhibitor, has ...
The Food and Drug Administration (FDA) has approved the combination of pembrolizumab (Keytruda, Merck Sharp & Dohme) with lenvatinib (Lenvima, Eisai Inc) for the first-line treatment of adult patients ...
A phase II trial of lenvatinib plus toripalimab and hepatic arterial infusion chemotherapy as a first-line treatment for advanced hepatocellular carcinoma (LTHAIC study). This is an ASCO Meeting ...
The study covered in this summary was published on Research Square as a preprint and has not yet been peer reviewed. Anaplastic thyroid cancer is a rare thyroid malignancy; disease-specific mortality ...
Learn everything you need to know about Lenvatinib-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...
The extended follow-up results are consistent with the primary analysis of the CLEAR trial, supporting the increased efficacy of first-line lenvatinib plus pembrolizumab compared with sunitinib in ...
Eisai’s multiple receptor tyrosine kinase inhibitor lenvatinib and Merck’s anti–PD-1 therapy pembrolizumab as a combination therapy for patients with renal cell carcinoma received the designation ...
TOKYO, Jul 29, 2025 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that its in-house discovered tyrosine kinase inhibitor, "LENVIMA(R)" (generic ...
Lenvatinib comes in the form of a capsule to be taken orally by mouth either with or without food. Follow the instructions and dose as directed by the physician. Since it can cause vomiting, it is ...
A review of clinical trial data on combination treatments for clear cell renal cell carcinoma. Chung-Han Lee, MD: One of the common approaches in addition to doing dual immune checkpoint inhibitors is ...
The appraisal committee considered evidence from a number of sources. See the committee papers for full details of the evidence. The patient and clinical experts explained that differentiated thyroid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results